“…Regarding RQ2, the carotenoid has shown atheroprotective potential, being beneficial in the control of risk factors for atherosclerosis, the main cause of the most common types of cardiovascular disease, as well as in the prevention and treatment of cardiometabolic syndrome (CMetS) (Jebari-Benslaiman et al, 2022;Santos et al, 2002;Somacal et al, 2022). Experimental results have shown that the carotenoid has the potential to act as a PPAR-γ agonist (Goto et al, 2010;Rohini et al, 2018;Wang et al, 2014), a substance of interest for the treatment of CMetS, inhibits the oxidation of human low-density lipoprotein (LDL) in vitro and improves the serum lipid profile in rabbits, increasing the levels of high-density lipoprotein and reducing the levels of triglycerides, autoantibodies, oxidized LDL, atherogenic index, as well as inhibiting lipid and protein oxidation in the aortic tissue of the animals (Somacal et al, 2022), as questioned in RQ3. Another study showed that norbixin inhibits lipid peroxidation, alters plasma lipid levels and paraoxonase/alisterase activities in in vivo tests under conditions of high fat intake, but as noted in RQ4, the doses tested were high and would not be suitable for humans (Santos et al, 2002).…”